^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AmoyDx Super-ARMS® EGFR Mutation Detection Kit

    Company:
    Amoy Diagnostics
    Type:
    CE Marked
    Related tests:
    over1year
    EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits. (PubMed, Pathol Oncol Res)
    Although non-plasma samples provided a superior T790M mutation detection rate, we found that liquid biopsy can offer a valuable tool for T790M mutation detection, when a tissue biopsy is not available. Alternatively, a liquid biopsy can be used as a screening test, when re-biopsy should be considered in case of wild-type results.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR T790M
    |
    cobas® EGFR Mutation Test v2 • AmoyDx Super-ARMS® EGFR Mutation Detection Kit
    almost2years
    Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial. (PubMed, JAMA Oncol)
    P2 | "This prospective phase 2 nonrandomized clinical trial suggests that for patients with clinically diagnosed advanced lung cancer with unknown pathological status, ctDNA-based EGFR genotyping could help decision-making in particular clinical situations, while still warranting future larger-scaled real-world exploration. ClinicalTrials.gov Identifier: NCT03346811."
    Journal • Clinical data • P2 data • Clinical • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR positive
    |
    AmoyDx Super-ARMS® EGFR Mutation Detection Kit
    |
    Conmana (icotinib)
    almost2years
    Molecular Alterations and Clinical Prognostic Factors in Resectable Non-Small Lung Cancer (IASLC-WCLC 2022)
    In resectable lung cancer, EGFRm prevalence, types of EGFRm, and PDL-1-positive prevalence were similar to advanced stage NSCLC. There was no EGFRm prevalence difference in each stage of disease (I-III). The OS was significantly longer in EGFRm patients which might be the effect of EGFR TKIs treatment in the recurrent patients.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • EGFR L858R • PD-L1 negative • ALK fusion • EGFR exon 18 mutation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • AmoyDx Super-ARMS® EGFR Mutation Detection Kit
    4years
    Detection and comparison of EGFR mutations from supernatants that contain cell-free DNA and cell pellets from FNA non-small cell lung cancer specimens. (PubMed, Cancer Cytopathol)
    "Discarded supernatants provided an adequate amount of cell-free DNA for EGFR detection, and this means that the pellets can be reserved for additional morphological and molecular analyses or to avoid repeat biopsies. Analyzing the EGFR status in cell supernatants and pellets might improve detection sensitivity and confer benefits to patients."
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR positive
    |
    AmoyDx Super-ARMS® EGFR Mutation Detection Kit